The Life Sciences team advised Arrakis Therapeutics, a biopharmaceutical company pioneering the discovery of a new class of small-molecule medicines that directly target RNA, on its $75 million Series B financing.
The financing was co-led by venBio Partners and Nextech Invest, with participation by new investors Omega Funds, HBM Healthcare Investments, GV (formerly Google Ventures), WuXi AppTec Venture Fund, and Alexandria Venture Investments, as well as all existing investors, Canaan Partners, Advent Life Sciences, Pfizer Ventures, Celgene Corporation, Osage University Partners and the estate of Henri Termeer. The proceeds from the Series B financing will enable Arrakis to build a pipeline of novel RNA‑targeted small molecules, with the goal of reaching clinical testing with one or more candidates
Arrakis Therapeutics has developed a proprietary platform to identify new RNA targets and drug candidates to treat diseases unaddressed by today’s medicines. It is building a proprietary pipeline of RNA-targeted small molecules (rSMs) focused on cancer and genetically validated targets in other disease areas.
The Goodwin team included partner Kingsley Taft and Sarah Smith.
For additional information, please read the company’s press release, and select media coverage in Endpoint Views, FierceBiotech, Stat, and Xconomy.